409 related articles for article (PubMed ID: 10028069)
1. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Meyerhoff A
Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
[TBL] [Abstract][Full Text] [Related]
2. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Berman JD
Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
[No Abstract] [Full Text] [Related]
3. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
4. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
[TBL] [Abstract][Full Text] [Related]
5. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
[TBL] [Abstract][Full Text] [Related]
6. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
Manfredi R; Marinacci G; Calza L; Passarini B
Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
[TBL] [Abstract][Full Text] [Related]
8. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
[No Abstract] [Full Text] [Related]
9. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
[TBL] [Abstract][Full Text] [Related]
10. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
11. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
Berman J
Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
[No Abstract] [Full Text] [Related]
12. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
[TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
Dilber E; Erduran E; Işik Y
Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
[TBL] [Abstract][Full Text] [Related]
16. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
17. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
19. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R
J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865
[TBL] [Abstract][Full Text] [Related]
20. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
